S

Stylus Medicine

In vivo genome editing for CAR-T

Associate Scientist - LNP Analytics

Bioprocess & BiomanufacturingPosted on Nov 10
Full-timeCambridge, MA, USA$105k - $115kIn-person

About the Job

Requirements

  • An undergraduate or master’s degree in biochemistry, chemical engineering, materials science, or a related field.
  • 2–4 years of industry or academic experience focused on lipid nanoparticle characterization.
  • A strong foundation in lipid chemistry, formulation development, and analytical techniques.
  • Familiarity with gene-editing modalities or nucleic acid delivery, such as CRISPR/Cas, base editing, mRNA, or DNA.
  • Ability to collaborate with cross-functional teams to meet project deliverables and timelines.
  • Ability to work independently, multitask effectively, and maintain strong written documentation.

Responsibilities

  • Leverage expertise in lipid chemistry, lipid nanoparticle formulation, and analytical characterization to advance novel gene-editing modalities across different stages of drug development.
  • Develop methods such as BLA, CBQCA, DLS, UPLC, HPLC-CAD, IP-RP HPLC, LC-MS/MS, CGE, BLI/SPR, ELISA, and ddPCR/qPCR to screen and support optimal lipid nanoparticle formulations for in vitro and in vivo applications.
  • Author standard operating procedures, study plans, and reports, and present findings to project teams and leadership.
  • Collaborate closely with cross-functional teams to support in vitro and in vivo experiments assessing biodistribution, safety, and efficacy of lipid nanoparticle formulations.
  • Foster external collaborations and stay abreast of emerging trends and innovations in lipid nanoparticle technology, proposing new approaches to enhance the company’s delivery platforms as appropriate.

Desired Qualifications

  • Prior experience characterizing targeted nanoparticles.

About the Company

Stylus Medicine

In vivo genome editing for CAR-T

Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.

Company size
11-50
Company stage
Series A
Total funding
$85M
Headquarters
Cambridge, MA
Founded
2022

Recently Posted Jobs

Explore more opportunities at Stylus Medicine

See more jobs